Skip to main content
. 2022 Mar 17;36(6):855–865. doi: 10.1111/jdv.18010

Figure 4.

Figure 4

Treat‐to‐target combined analysis. Proportion of patients achieving combined treatment targets (a) PASI ≤ 3 and DLQI ≤ 5 and (b) PASI ≤ 1 and DLQI 0/1, at weeks 16 and 52 (NRI). Numbers indicate the percentage of patients in each group. DLQI, Dermatology Life Quality Index; NRI, non‐responder imputation; PASI, Psoriasis Area and Severity Index; RZB, risankizumab; UST, ustekinumab. ***P < 0.001.